Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults Treated for a Tumoral Disease

associated with a high rate ofmucositis: conventional chemotherapy or High Dose Chemotherapy (HDC) conditioning regimens with Hematological Stem Cell Transplantation (HSCT).

  • 0 views
  • 04 Mar, 2021
  • 1 location
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months.

cell transplantation
high dose chemotherapy
velcade
remission
melphalan
  • 16 views
  • 07 Nov, 2020
  • 7 locations
TCD Followed by autoSCT for Newly Diagnosed MM Patients

high dose chemotherapy with autologous stem cell transplantation and TD maintenance therapy for the patients with newly diagnosed multiple myeloma.

high dose chemotherapy
maintenance therapy
thalidomide
cell transplantation
  • 5 views
  • 07 Nov, 2020
  • 1 location
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent years. However, elderly patients ineligible for receiving high dose chemotherapy and allo-HSCT, have

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Prevention of Oral Mucositis Using Photobiomodulation Therapy

Oral mucositis is a significant and common toxicity experienced by patients who receive high-dose chemotherapy as a preparatory regimen for a hematopoietic cell transplant (HCT). Furthermore

mucositis
high dose chemotherapy
  • 3 views
  • 17 Feb, 2021
  • 1 location
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.

. Instead of the high dose chemotherapy usually given before a transplant, this research study uses a new pre-treatment combination of two drugs, Anti-CD45 and CAMPATH-1H. Anti-CD45 and CAMPATH-1H

anemia
fludarabine
campath
graft versus host disease
  • 34 views
  • 07 Nov, 2020
  • 1 location
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

This phase II multi-institutional trial will explore the safety and efficacy of lenalidomide monotherapy given as maintenance therapy following salvage chemo-immunotherapy in patients with relapsed or refractory chemosensitive diffuse large B-cell lymphoma

rituximab
high dose chemotherapy
lenalidomide
cancer chemotherapy
b-cell lymphoma
  • 28 views
  • 07 Nov, 2020
  • 1 location
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of

large b-cell lymphoma
aggressive non-hodgkin's lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
hodgkin's disease
  • 63 views
  • 28 Jan, 2021
  • 68 locations